Feature | March 14, 2013

Research Shows Niacin Added to Statin Therapy Increases HDL Cholesterol Levels, But Does Not Improve HDL Functionality

March 14, 2013 — While two large clinical trials recently showed that adding niacin to statin therapy failed to improve clinical outcomes despite a significant increase in HDL-C levels, little is known about exactly why the increased HDL-C levels did not reduce the risk of cardiovascular events, including heart attack and stroke. Now, researchers from Perelman School of Medicine at the University of Pennsylvania are showing in a small study that while niacin increased measured levels of HDL-C, it did not improve the functionality of HDL. This may provide an explanation for the failure of niacin to further reduce cardiovascular risk. These study results were reported at the 62nd annual scientific session of the American College of Cardiology in San Francisco.

“There is a major need to identify additional agents to target residual cardiovascular risk beyond the use of statins,” said senior study author Daniel J. Rader, M.D., professor of medicine and chief of the division of translational medicine and human genetics at the University of Pennsylvania. “Niacin is one of the oldest players in this field and is often used clinically to increase HDL cholesterol levels. However, much to the disappointment of the medical community, recent trials of niacin added to standard LDL-lowering therapy with statins failed to show benefit in improving cardiovascular outcomes. There has been substantial recent interest in the function of HDL independent of HDL cholesterol levels. We performed a small trial to examine how niacin modulated a classic function of HDL, namely its ability to promote cholesterol removal from cells.”

Previous work from Pennsylvania investigators has shown that a measure of HDL function, cholesterol efflux capacity, is more strongly related to coronary artery disease than HDL cholesterol levels. To assess the change in functional capacity of HDL with niacin therapy, they randomized 39 patients with known carotid atherosclerosis to either simvastatin plus placebo or simvastatin plus extended-release niacin. After six months of therapy, they measured HDL-C levels and assessed functional properties using two tests — cholesterol efflux capacity (a measure of how well HDL removes cholesterol from lipid-loaded cells) and the HDL inflammatory index (which quantifies the antioxidant properties as it relates to preventing the oxidation of LDL).

As expected, they saw a 29 percent increase in HDL cholesterol with the addition of niacin to statin therapy, compared to a two percent increase in those treated with statin only. However, on the measures of cholesterol efflux capacity and the HDL inflammatory index, they saw no significant changes in HDL function.

“Based on our research, we now know that the addition of niacin to statin does not improve HDL function, providing a possible explanation for the failure of previous large scale trials,” said lead study author Amit Khera, M.D., a former member of the Rader lab who is now completing his residency at the Brigham and Women’s Hospital in Boston. “The assays we used to measure HDL function are robust and reproducible, thus potentially useful in the early clinical screening of new HDL-targeted therapies to understand how/if they might work.”

Other study authors from the University of Pennsylvania include Parin J. Patel, M.D., and Muredach P. Reilly, MBBCH, MSC.

Investigator-initiated grants were received from Merck and KOS (now Abbott) Pharmaceuticals for the study, though they had no influence on study design, analysis or abstract preparation. The research team also received support from the Penn Cardiovascular Institute and the NIH-CTSA supported Penn Clinical and Translational Research Center (CTRC).

For more information: www.pennmedicine.org

Related Content

News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in
BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
Biotronik, BioCONTINUE study, CRT-D, defibrillator, cardiac resynchronization therapy device, heart failure, first replacement
News | Cardiac Resynchronization Therapy Devices (CRT)| August 17, 2015
Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to...
Medtronic, Endurant Evo AAA, stent graft system, first European cases
News | Stent Grafts| August 13, 2015
Medtronic plc announced that the first two European patient cases with the Endurant Evo AAA stent graft system were...
zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research
Technology | ECG| August 13, 2015
iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a...
NICE, U.K., edoxaban, Lixiana, VTE, venous thromboembolism, deep vein thrombosis, pulmonary embolism
News | Deep Vein Thrombosis| August 12, 2015
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help patients suffering...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
ACC, Boehringer Ingelheim, Diabetes Collaborative Registry, American College of Cardiology
News | Cardiac Diagnostics| August 07, 2015
The American College of Cardiology (ACC) has announced that Boehringer Ingelheim is the newest industry sponsor of The...
Mayo Clinic, LVAD, study, heart failure, restrictive cardiomyopathy, RCM

Thoratec HeartMate II image courtesy of Thoratec

News | Ventricular Assist Devices (VAD)| August 07, 2015
Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating...
Overlay Init